These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22891197)

  • 1. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
    Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
    Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection.
    Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K
    Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
    Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous tumors of the ovary: a review.
    Hart WR
    Int J Gynecol Pathol; 2005 Jan; 24(1):4-25. PubMed ID: 15626914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
    Hunter SM; Anglesio MS; Sharma R; Gilks CB; Melnyk N; Chiew YE; deFazio A; ; Longacre TA; Huntsman DG; Gorringe KL; Campbell IG
    Clin Cancer Res; 2011 Dec; 17(23):7273-82. PubMed ID: 21976534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
    Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
    Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
    Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
    Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
    Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
    Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
    Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
    Li XS; Sun J; He XL
    Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
    Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
    Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
    Werness BA; DiCioccio RA; Piver MS
    Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency and prognostic role of P53 and P16 immunoexpression in primary ovarian mucinous tumors.
    Nergiz D; Yıldırım HT; Süren D; Sadullahoğlu C; Yıldırım Ş; Üreyen I
    Ann Diagn Pathol; 2024 Oct; 72():152330. PubMed ID: 38772285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.